Zhaoke Ophthalmology (HKSE:06622) Volatility: 38.84% (As of Sep. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06622 Zhaoke Ophthalmology Ltd HKSE:06622
47 GF Score
Price HK$2.53
GF Value HK$2.60
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Zhaoke Ophthalmology Volatility?

Zhaoke Ophthalmology HKSE:06622 +1.61% 47 Volatility is 38.84% as of Sep. 04, 2026. GuruFocus rates HKSE:06622 with a GF Score™ of 47/100 and a GF Value™ of HK$2.60 (Fairly Valued). The stock has 5 warning signs investors should review.

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2026-09-04), Zhaoke Ophthalmology's Volatility is 38.84%.


Zhaoke Ophthalmology  (HKSE:06622) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.


Zhaoke Ophthalmology Volatility Related Terms


HKSE:06622 vs VRTX, REGN, MRNA: Volatility Comparison

For the Biotechnology subindustry, Zhaoke Ophthalmology's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhaoke Ophthalmology Volatility vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zhaoke Ophthalmology's Volatility distribution charts can be found below:

* The bar in red indicates where Zhaoke Ophthalmology's Volatility falls into.


HKSE:06622
47GF Score
Zhaoke Ophthalmology Ltd HKSE:06622
Volatility is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhaoke Ophthalmology  (HKSE:06622) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * 12
= 1/(n-1) ∑(Ri - R')^2 * 12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Volatility →
What does a Volatility of 38.84% mean?
Zhaoke Ophthalmology (HKSE:06622) has a Volatility of 38.84% as of Sep. 04, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Zhaoke Ophthalmology and its competitors.
Is Zhaoke Ophthalmology's Volatility too high?
Zhaoke Ophthalmology's current Volatility is 38.84%. Overall, Zhaoke Ophthalmology has a GF Score™ of 47/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zhaoke Ophthalmology's Volatility compare to VRTX and REGN?
Zhaoke Ophthalmology's Volatility of 38.84% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Zhaoke Ophthalmology and its competitors. Zhaoke Ophthalmology's current Volatility is 38.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhaoke Ophthalmology stock overvalued right now?
Based on GuruFocus' analysis, Zhaoke Ophthalmology (HKSE:06622) is currently considered Fairly Valued. The stock's GF Value™ is HK$2.60, compared to a current price of HK$2.53 — trading 2.7% below its estimated fair value. The current Volatility is 38.84%. Zhaoke Ophthalmology's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For Zhaoke Ophthalmology (HKSE:06622), the current Volatility is 38.84% as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhaoke Ophthalmology (HKSE:06622) Overvalued in 2026?

Based on GuruFocus' analysis, Zhaoke Ophthalmology stock appears to be undervalued. The current stock price of HK$2.53 is trading 2.7% below its estimated GF Value™ of HK$2.60. GuruFocus considers Zhaoke Ophthalmology to be Fairly Valued.

Key valuation signals for HKSE:06622:

  • Volatility: 38.84%
  • GF Value™: HK$2.60 vs. price of HK$2.53 (2.7% below fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the HKSE:06622 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Zhaoke Ophthalmology Business Description

Other Exchanges 9FX:Germany
Address No. 1 Meide 3rd Road, Pearl River Industrial Park, Nansha District, Guangdong Province, Guangzhou, CHN
Zhaoke Ophthalmology Ltd is an ophthalmic pharmaceutical company dedicated to the research, development, manufacture and commercialization of therapies that address unmet medical needs. The company has three flagship drug assets progressing towards potential market approval: NVK002 for myopia, CsA Ophthalmic Gel for DED and TAB014 for wAMD; and two drug assets in the clinical stage BRIMOCHOL PF for presbyopia and ZKY001 for corneal epithelial defects. Geographically the company operates in Hong Kong, Chinese Mainland, South Korea, and Others, of which it generates maximum revenue from Chinese Mainland.
47GF Score

Get the complete analysis for HKSE:06622

Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.53
Price
HK$2.60
GF Value